Claims for Patent: 6,566,395

Summary for Patent: 6,566,395

Title:	Methods of treating proliferative disorders
Abstract:	Disclosed are methods and compositions for treating proliferative disorders, such as cancers, blood vessel disorders, fibrotic disorders and acute or chronic rejection of transplanted organs, tissue or cells, using compounds of formula I or a tautomeric isomer thereof: ##STR1## wherein R.sup.1 and R.sup.2 are as defined; or a pharmaceutically-acceptable salt or pro-drug thereof.
Inventor(s):	Moran; Stanford Mark (Orinda, CA)
Assignee:	BioMedicines, Inc. (Alameda, CA)
Application Number:	09/577,689
Patent Claims:	1. A method of treating a mammal having a proliferative disorder comprising administering to said mammal a proliferation-inhibiting amount of a compound of formula II or a tautomeric isomer thereof: ##STR10## or a pharmaceutically acceptable salt or pro-drug thereof. 2. A method of inhibiting tumor growth in a mammal having a solid tumor comprising administering to said mammal a tumor growth-inhibiting amount of a compound of formula II or a tautomeric isomer thereof: ##STR11## or a pharmaceutically-acceptable salt or pro-drug thereof. 3. The method of claim 1 wherein the compound of formula II is administered in combination with one or more immunosuppressive agents. 4. The method of claim 3 wherein each immunosuppressive agent is independently selected from the group consisting of azathioprine, corticosteroids, cyclosporin, cyclophosphamide, mycophenolic acid or congeners thereof and monoclonal or polyclonal antibodies. 5. The method of claim 1, wherein the proliferative disorder is cancer. 6. The method of claim 5, wherein the cancer is a solid tumor cancer, a bone marrow cell cancer or lymphatic or a lymph node-related cancer. 7. The method of claim 1, wherein the proliferative disorder is selected from the group consisting of a blood vessel proliferative disorder, fibrotic disorder, and an acute or chronic rejection of a transplanted organ, tissue or cells. 8. The method of claim 1, wherein the proliferation-inhibiting amount of the compound of formula II ranges from about 0.001 mg/kg/day to about 2000 mg/kg/day. 9. The method as in either claim 1 or claim 2, wherein the compound of formula II is administered orally, intravenously, parenterally or transdermally. 10. The method as in either claim 1 or claim 2, wherein the compound of formula II is administered in combination with one or more chemotherapeutic agents. 11. The method of claim 10, wherein each chemotherapeutic agent is independently selected from the group consisting of androgens, asparaginase, azathioprine, 5-azacitidine, BCG, bleomycin, busulfan, carbetimer, carboplatin chlorambucil, cisplatin, corticosteroids, cyclophosphamide, cytarabine, dacarbazine, dactinomicin, daunomycin, doxorubicin, epirubicin, estrogens, etoposide, fadrazole, 5-flurouracil, gemcitabine, hydroxyurea, ifosfamide, interferon alpha, interferon beta, interferon gamma, an interleukin, isotretinoin, lomustine, melphalan, 6-mercaptopurine, methotrexate, mitomycin-c, mitotane, mitoxantrone, paclitaxel, pentostatin, procabazine, progestins, rituximab, streptozocin, tamoxifen, taxotere, teniposide, thioguanine, thiotepa, topotecan, toremifene, tretinoin, uracil mustard, vinblastine, vincristine and vinorelbine. 12. The method as in either claim 1 or claim 2 wherein the compound of formula II is administered in combination with radiation therapy. 13. The method as in either claim 1 or claim 2 wherein the compound of formula II is administered in combination with ablative or partially ablative surgery. 14. A method of treating ovarian cancer in a mammalian patient comprising administering to said patient a proliferation-inhibiting amount of a compound of formula II or a tautomeric isomer thereof: ##STR12## or a pharmaceutically-acceptable salt or pro-drug thereof; and further wherein the proliferation-inhibiting amount provides a concentration of the compound of formula II in the mammalian patient which treats the ovarian cancer. 15. A method of treating colon cancer in a mammalian patient comprising administering to said patient a proliferation-inhibiting amount of a compound of formula II or a tautomeric isomer thereof: ##STR13## or a pharmaceutically-acceptable salt or pro-drug thereof; and further wherein the proliferation-inhibiting amount provides a concentration of the compound of formula II in the mammalian patient which treats the colon cancer. 16. A method of treating breast cancer in a mammalian patient comprising administering to said patient a proliferation-inhibiting amount of a compound of formula II or a tautomeric isomer thereof: ##STR14## or a pharmaceutically-acceptable salt or pro-drug thereof; and further wherein the proliferation-inhibiting amount provides a concentration of the compound of formula II in the mammalian patient which treats the breast cancer. 17. A method of treating lung cancer in a mammalian patient comprising administering to said patient a proliferation-inhibiting amount of a compound of formula II or a tautomeric isomer thereof: ##STR15## or a pharmaceutically-acceptable salt or pro-drug thereof; and further wherein the proliferation-inhibiting amount provides a concentration of the compound of formula II in the mammalian patient which treats the lung cancer.

Details for Patent 6,566,395

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2019-05-25
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2019-05-25
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2019-05-25